Retrospective anti–EGFR-treated tumor samples from 205 patients were identified from the discovery and validation (CO.20) cohorts after clinical review and quality control of the tumor blocks and tumor-derived RNA (Fig 1A). This evidence concerns the gene EGFR and neoplasm.